Effects of VEGF Gene Polymorphisms on BEV Responsiveness in a Sample of Iraqi Colorectal Cancers Using HRM - PCR
Keywords:VEGF Gene, Polymorphisms, BEV Therapeutic, Colorectal Cancers, HRM – PCR
Background: Vascular endothelial growth factor (VEGF) have a vital role in the molecular genetic events
of angiogenesis and vasculogenesis, so it is involved in the development of cancer. Single nucleotide
polymorphisms (SNP) in VEGF gene has been announced as a risk factor in colorectal cancer. Bevacizumab
(BEV) is an angiogenesis inhibitor that curb the binding of VEGF to its receptors obstructing the angiogenesis
process. Objective: The ideal goal of ongoing study lies in revealing the effect of rs699947 (-2578 C/A (and
rs833061 (-460C/T( polymorphisms in the promoter of VEGF gene on the development of colorectal cancer
and on the BEV responsiveness in a sample of Iraqi patients using High Resolution Melting Analysis (HRM)
analysis. Methodology: Venous blood samples were collected from 25 colorectal cancer patients with
response to BEV treatment and 25 with BEV resistant and 25 apparently healthy individuals as control
group who matched with patients in age and gender. Results: AA and CA polymorphisms A allele of
rs699947 (-2578 C/A) and TT and CT polymorphisms and T allele of rs833061 (-460C/T( were represent
a risk factor on the occurrence of the colorectal cancer. It has been found that CC and CA polymorphism
of the VEGF - 2578 C/A and CT genotype of the VEGF -460 C/T polymorphism might be a predictive
factors of responsiveness to BEV chemotherapy in CRC patients. Conclusion: These outcomes confirm the
essential role that VEGF polymorphisms play in the occurrence of CRC and the correlation between SNPs in
VEGF promoter region and the BEV responsiveness. With this, further research and investigation of VEGF
polymorphisms could allow for its use in identifying risk factors for the development of CRC and increasing
its predictive value for anti-VEGF cancer therapies.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Re use and mixing of content policy- We follow Creative Commons Licence Policy. We follow CC BY. Please refer below for all details
This license lets others distribute, remix, adapt, and build upon our work, even commercially, as long as they credit us for the original creation.
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions